Evaluation of an Exercise Intervention for Vincristine Induced Peripheral Neuropathy in Pediatric Cancer Patients
NCT ID: NCT03430674
Last Updated: 2023-03-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
10 participants
INTERVENTIONAL
2018-07-01
2019-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Aim 1: Evaluate the feasibility and acceptability of EX as an intervention for VIPN in pediatric patients with ALL.
Aim 2: Estimate preliminary effect sizes of the EX intervention.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exercise and Nutrition Interventions During Chemotherapy
NCT03021174
Vincristine-induced Peripheral Neuropathy in Adult Survivors of Childhood and Adolescent Leukemia
NCT05759052
Heading Off Peripheral Neuropathy With Exercise
NCT00869804
Effects of Transcutaneous Electrical Nerve Stimulation on Chemotherapy-Induced Peripheral Neuropathy
NCT04367480
Pilot Study of Strength and Balance Training Program for Persons With Oxaliplatin Induced Neuropathy
NCT01422993
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This visit may take up to 1.5 hours total.
* The subject's exercise therapist will meet with them to discuss what they can expect throughout the program period. The subject will receive their exercise DVD to be used for at-home exercise sessions.
* The subject will be asked questions about how they are feeling and their general well-being. The subject will also be asked to complete several questionnaires about their neuropathy, confidence level about completing the program, support and expectations.
* The subject will be given a Fitbit with instructions about how and when to use it.
* The subject will have a sample of blood collected (15mL or about 1 tablespoon). The study team will time this blood draw to occur when they are already having blood drawn for routine clinical treatment.
* The subject will have a physical fitness test, which includes body measurements such as weight, height and blood pressure; also tests for physical strength, endurance and oxygen consumption. At the same time the subject is given the physical fitness test they will also be asked to not eat for 1 hour before this session.
* The subject will complete their first exercise session with their therapist.
Weeks 6-13:
During weeks 6-13 (8 weeks total), the subject will be asked to exercise for at least 15 minutes 6 times per week using the instructional DVD that was provided to them. The exercise the subject does will be tailored to their age range (either age 5-10 or 11-18) and will consist of strengthening and aerobic activities. The subject will also be asked to keep an exercise log that is provided by the study to record their exercise activity including how they felt when they exercised. The subject will be asked to perform one of their exercise sessions during weeks 8, 10, and 12 at Riley Hospital with their exercise therapist. The study team will coordinate this visit to occur during one of their regularly scheduled office visits. Post-program visit (week 14) This visit may take up to 1.5 hours total.
* The subject will be asked questions about how they are feeling and their general well-being. The subject will also be asked to complete several questionnaires about your neuropathy, confidence level about completing the program, support and expectations.
* The subject will have a sample of blood collected (15mL or about 1 tablespoon). The study team will time this blood draw to occur when they are already having blood drawn for routine clinical treatment.
* The subject will repeat the physical fitness test, which includes body measurements such as weight, height and blood pressure; also tests for physical strength, endurance and oxygen consumption. During the last session (week 14) the subject will also be asked to not eat for 1 hour before this session.
* The subject will be asked to complete a satisfaction survey.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exercise Intervention
Clinic and at home exercise sessions.
Exercise
Exercise, questionnaires and blood draws.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exercise
Exercise, questionnaires and blood draws.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. age ≥ 5 and ≤ 18 years,
2. have been diagnosed with acute lymphoblastic leukemia (ALL),
3. will undergo the standard of care treatment for ALL with vincristine.
4. will have a TNS-PV score of \>3 at week 6
Exclusion Criteria
1. baseline peripheral neuropathy greater than grade 1 (prior to receiving any doses of vincristine),
2. evidence of significant liver dysfunction,
3. Down's Syndrome,
4. pregnancy,
5. severe illness or infection,
6. current active treatment with erythropoietin,
7. administration of vitamin supplements above 100% of the recommended daily allowance
5 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Indiana University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jamie Renbarger
Professor of Pediatric Cancer Research
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jamie Renbarger, MD
Role: PRINCIPAL_INVESTIGATOR
Riley Hospital for Children - Indiana University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Riley Hospital for Children - Indiana University
Indianapolis, Indiana, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1708708583
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.